Cover Image
市場調查報告書

Lycera Corp. : 產品平台分析

Lycera Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257842
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Lycera Corp. : 產品平台分析 Lycera Corp. - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 32 Pages
簡介

Lycera Corp.正在致力於藥物發明和開發自體免疫疾病患者所用之小分子免疫刺激劑。該公司同時也在開發慢性風濕病,乾癬和發炎性腸道疾病類疾病治療用之新精選之口服免疫刺激劑。

本報告提供Lycera Corp.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,再加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Lycera Corp.的基本資料

Lycera Corp.概要

  • 主要資訊
  • 企業資料

Lycera Corp.:R&D概要

  • 主要的治療範圍

Lycera Corp.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Lycera Corp.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Lycera Corp.:藥物簡介

  • LYC-30937
  • LYC-51194
  • LYC-51661
  • Small Molecule to Antagonize ROR-Gamma for CNS, Autoimmune and Gastrointestinal Disorders
  • Small Molecule to Inhibit Rho Kinase for Fibrosis
  • Small Molecules for Cancer
  • Small Molecules to Agonize ROR gamma for Breast Cancer
  • Small Molecules to Inhibit HDAC6 for Autoimmune Diseases
  • Small Molecules for Autoimmune Disorders

Lycera Corp.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Lycera Corp.:最近的開發平台趨勢

Lycera Corp.:暫停中的計劃

Lycera Corp.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07565CDB

Summary

Global Markets Direct's, 'Lycera Corp. - Product Pipeline Review - 2015', provides an overview of the Lycera Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lycera Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lycera Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lycera Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lycera Corp.'s pipeline products

Reasons to buy

  • Evaluate Lycera Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lycera Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lycera Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lycera Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lycera Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lycera Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lycera Corp. Snapshot
    • Lycera Corp. Overview
    • Key Information
    • Key Facts
  • Lycera Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Lycera Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Lycera Corp. - Pipeline Products Glance
    • Lycera Corp. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Lycera Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Lycera Corp. - Drug Profiles
    • LYC-30937
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LYC-51194
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LYC-51661
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for CNS, Autoimmune and Gastrointestinal Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Rho Kinase for Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize ROR gamma for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Autoimmune Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lycera Corp. - Pipeline Analysis
    • Lycera Corp. - Pipeline Products by Target
    • Lycera Corp. - Pipeline Products by Route of Administration
    • Lycera Corp. - Pipeline Products by Molecule Type
    • Lycera Corp. - Pipeline Products by Mechanism of Action
  • Lycera Corp. - Recent Pipeline Updates
  • Lycera Corp. - Dormant Projects
  • Lycera Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lycera Corp., Key Information
  • Lycera Corp., Key Facts
  • Lycera Corp. - Pipeline by Indication, 2015
  • Lycera Corp. - Pipeline by Stage of Development, 2015
  • Lycera Corp. - Monotherapy Products in Pipeline, 2015
  • Lycera Corp. - Phase I, 2015
  • Lycera Corp. - Preclinical, 2015
  • Lycera Corp. - Discovery, 2015
  • Lycera Corp. - Pipeline by Target, 2015
  • Lycera Corp. - Pipeline by Route of Administration, 2015
  • Lycera Corp. - Pipeline by Molecule Type, 2015
  • Lycera Corp. - Pipeline Products by Mechanism of Action, 2015
  • Lycera Corp. - Recent Pipeline Updates, 2015
  • Lycera Corp. - Dormant Developmental Projects,2015
  • Lycera Corp., Other Locations

List of Figures

  • Lycera Corp. - Pipeline by Top 10 Indication, 2015
  • Lycera Corp. - Pipeline by Stage of Development, 2015
  • Lycera Corp. - Monotherapy Products in Pipeline, 2015
  • Lycera Corp. - Pipeline by Top 10 Target, 2015
  • Lycera Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Lycera Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Lycera Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top